59.5 (39–75) | |
Male | 55 (57.3%) |
Female | 41 (42.7%) |
0 | 35 (36.4%) |
1 | 57 (59.4%) |
2 | 4 (4.2%) |
Current smokers | 56 (58.3%) |
Never smokers | 18 (18.8%) |
Former smokers | 18 (18.8%) |
Unknown | 4 (4.2%) |
Stage ≤ IIIB | 9 (9.4%) |
Stage IIIC | 1 (1.0%) |
Stage IV | 86 (89.6%) |
Yes | 18 (18.7%) |
No | 78 (81.3%) |
0% | 35 (36.5%) |
1–49% | 34 (35.4%) |
≥ 50% | 16 (16.7%) |
Unknown | 11 (11.5%) |
|
5 (5.2%) |
|
0 (0.0%) |
|
0 (0.0%) |
|
7 (7.3%) |
|
1 (1.0%) |
|
3 (3.1%) |
|
1 (1.0%) |
Second-line therapy after first line combination ChT-ICI | 24 (25%) |
Second-line therapy after first-line platinum-based ChT | 7 (7.3%) |
Third-line therapy after first-line ChT and second-line ICI | 47 (49.0%) |
Third-line therapy after first-line ICI and second-line ChT | 13 (13.5%) |
Fourth or later-lines | 3 (3.1%) |
Other¶ | 2 (2.1%) |
CR | 0 (0.0) |
PR | 18 (18.8) |
SD | 37 (38.5) |
PD | 31 (32.3) |
ORR (CR+PR) | 18 (18.8) |
DCR (CR+PR+SD) | 55 (57.3) |
Non-evaluable | 10 (10.4) |
Median PFS, months | 3.0 (95% CI: 3–5) |
Median OS, months | 8.0 (95% CI: 7–10) |
CR, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
PR, n (%) | 7 (29.2) | 1 (14.3) | 9 (19.1) | 1 (7.7) | 0 (0.0) |
SD, n (%) | 9 (37.5) | 2 (28.6) | 18 (38.3) | 7 (53.8) | 1(33.3) |
PD, n (%) | 3 (12.5) | 3 (42.9) | 18 (38.3) | 5 (38.5) | 2(66.7) |
ORR, n (%) | 7 (29.2) | 1 (14.3) | 9 (19.1) | 1 (7.7) | 0 (0.0) |
DCR, n (%) | 16 (66.7) | 3 (42.9) | 27 (57.4) | 8 (61.5) | 1(33.3) |
Non-evaluable, n (%) | 5 (20.8) | 1 (14.3) | 2 (4.3) | 0 (0.0) | 0 (0.0) |
Total | 53 (55.2) | 8 (8.3) |
Diarrhea | 29(30.2) | 1 (1.0) |
Elevated liver enzymes | 17(17.7) | 6 (6.3) |
Rash | 6 (6.2) | |
Neutropenia | 4 (4.2) | |
Peripheral neuropathy | 3 (3.1) | |
Stomatitis | 2 (2.1) | |
Nausea | 2 (2.1) | |
Hypertension | 2 (2.1) | 1 (1.0) |